BCHE and Lewy body dementia: An accurate diagnosis of DLB at the prodromal stage would be an important advance in the pharmacological management, as cholinesterase inhibitors (ChEIs) have good responsiveness for patients with Lewy body dementia (LBD) including DLB and Parkinson’s disease dementia (PDD), although a careful monitoring of treatment compliance and side effects is required [5].